Berberine (CAS 2086-83-1): AMPK Activator and LDLR Upregulator for Metabolic and Inflammatory Research

Executive Summary: Berberine (CAS 2086-83-1) is a well-studied isoquinoline alkaloid primarily isolated from Cortex Phellodendri Chinensis, with a molecular weight of 336.36 Da and formula C₂₀H₁₈NO₄ (APExBIO). It robustly activates AMP-activated protein kinase (AMPK), leading to beneficial modulation of glucose and lipid metabolism, anti-inflammatory signaling, and antimicrobial effects (adrenomedullin.us). Berberine upregulates LDL receptor (LDLR) mRNA and protein in HepG2 and Bel-7402 cell lines in a dose-dependent manner (maximal effect at 15 μg/mL) and significantly lowers serum total and LDL cholesterol in hyperlipidemic hamsters at 50–100 mg/kg/day, correlating with increased hepatic LDLR expression (Li et al., 2025). It is insoluble in water/ethanol but dissolves (≥14.95 mg/mL) in DMSO, with optimal solubility at 37°C or via ultrasonication. The product is provided by APExBIO (SKU N1368) and is widely used in metabolic, cardiovascular, and inflammation research workflows.

Biological Rationale

Berberine is a prototypical isoquinoline alkaloid extracted from traditional medicinal plants, notably Cortex Phellodendri Chinensis (APExBIO). Its primary biological value derives from its ability to act as an AMPK activator, a central regulatory kinase in cellular energy homeostasis. AMPK activation orchestrates multiple metabolic processes, including increased glucose uptake, enhanced fatty acid oxidation, and inhibition of cholesterol biosynthesis. Berberine’s pharmacological profile includes modulation of metabolic, inflammatory, and microbial pathways, positioning it as a translational tool for research into diabetes, obesity, cardiovascular diseases, and acute inflammation (glucagon-19-29-human.com). Notably, berberine’s effect on LDL receptor expression and NLRP3 inflammasome inhibition provides a mechanistic rationale for its use in lipid metabolism and inflammation research (adrenorphin.net), extending the landscape beyond traditional metabolic models.

Mechanism of Action of Berberine (CAS 2086-83-1)

Berberine exerts its primary effects via activation of AMP-activated protein kinase (AMPK). This phosphorylation event triggers downstream signaling that regulates glucose and lipid homeostasis. In human hepatoma cell lines (HepG2 and Bel-7402), berberine induces a dose-dependent increase in LDL receptor (LDLR) mRNA and protein expression, with maximal upregulation at 15 μg/mL (APExBIO product data). Berberine also modulates the NLRP3 inflammasome, a cytosolic sensor complex integral to sterile inflammation and pyroptotic cell death pathways (Li et al., 2025). It interferes with NEK7-NLRP3 interactions, suppressing inflammasome activation and downstream cytokine release (IL-1β, IL-18), independently of AIM2 inflammasome engagement (adrenorphin.net). Additional reported actions include inhibition of mitochondrial respiratory chain complex I and modulation of gut microbiota in animal models, though these are context-dependent.

Evidence & Benchmarks

• Berberine (CAS 2086-83-1) upregulates LDLR mRNA and protein in HepG2 and Bel-7402 cells in a dose-dependent manner, with maximal effect at 15 μg/mL (APExBIO).
• Oral administration of berberine at 50–100 mg/kg/day for 10 days significantly reduces serum total cholesterol and LDL cholesterol in hyperlipidemic golden hamsters, concomitant with increased hepatic LDLR expression (Li et al., 2025).
• Berberine activates AMPK, resulting in decreased hepatic gluconeogenesis and improved glucose utilization in rodent models (glucagon-19-29-human.com).
• Berberine inhibits the NLRP3 inflammasome by interfering with NEK7-NLRP3 interactions, reducing pyroptosis and pro-inflammatory cytokine secretion in acute kidney injury models (Li et al., 2025).
• Berberine has a solubility of ≥14.95 mg/mL in DMSO and is insoluble in water and ethanol; optimal dissolution is achieved at 37°C or with ultrasonication (APExBIO).

This article extends the mechanistic focus of Berberine: AMPK Activator for Metabolic and Inflammation Research by providing new evidence on NLRP3 inflammasome modulation and its translational relevance. It also clarifies and benchmarks LDLR upregulation and anti-inflammatory effects, updating the context provided in Berberine (CAS 2086-83-1): Mechanistic Leverage and Strategy.

Applications, Limits & Misconceptions

Berberine is widely used in preclinical models of metabolic diseases, including diabetes, obesity, and dyslipidemia, due to its robust AMPK activation and LDLR upregulation. Inflammation studies utilize berberine’s capacity to inhibit NLRP3 inflammasome–driven pyroptosis. The product is also employed in cardiovascular disease models and acute kidney injury protocols. However, extrapolation to clinical efficacy must be cautious due to differences in pharmacokinetics, bioavailability, and off-target effects. Berberine’s poor solubility in aqueous and alcoholic solvents limits its use in some in vitro protocols, requiring DMSO and careful solubilization steps.

Common Pitfalls or Misconceptions

• Berberine is not soluble in water or ethanol; use DMSO and optimize dissolution with heat or ultrasonication.
• Short-term storage of solutions (< -20°C) is feasible, but long-term storage leads to degradation and loss of potency.
• Berberine’s effects in cell lines and animal models do not guarantee clinical efficacy due to poor oral bioavailability and rapid metabolism.
• Inhibition of the STING pathway by berberine is modest compared to its pronounced effects on the NLRP3 inflammasome (Li et al., 2025).
• Berberine does not act as a broad-spectrum anti-inflammatory in all models; effects are context- and pathway-dependent.

Workflow Integration & Parameters

For research use, Berberine (CAS 2086-83-1) is typically prepared as a concentrated stock in DMSO (≥14.95 mg/mL), with dissolution facilitated at 37°C or by ultrasonic shaking (APExBIO N1368 kit). For in vitro experiments, working concentrations in the range of 1–15 μg/mL are standard for LDLR upregulation in hepatoma cells. In vivo protocols for hyperlipidemia or inflammation models often employ 50–100 mg/kg/day by oral gavage for 7–14 days. Solutions should be used promptly after preparation and stored below -20°C, protected from light and moisture. Detailed troubleshooting and sensitivity considerations can be found in Berberine (CAS 2086-83-1): Reliable Reagent for Cell-Based Assays, which this article updates by integrating inflammasome-focused workflows and benchmarks.

Conclusion & Outlook

Berberine (CAS 2086-83-1) is a rigorously characterized AMPK activator and LDLR upregulator, with validated applications in metabolic and inflammation research. Its robust inhibition of the NLRP3 inflammasome and reproducible effects on lipid metabolism make it a versatile tool for translational studies. APExBIO’s research-grade Berberine (SKU N1368) supports consistent outcomes when protocols are optimized for solubility and storage. Ongoing work will clarify its utility in emerging disease models, including acute inflammation and kidney injury (mtorinhibitor.com), and enable the design of next-generation therapeutic strategies.